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Objective. Adult granulosa cell tumors (AGCTs) represent 2%–5% of all ovarian malignancies. The aim of this study was to analyze
clinical and pathohistological parameters and their impact on recurrence, overall, and disease-free survival in FIGO stage I AGCT
patients. Methods. The tumor specimens analyzed in this retrospective study were obtained from a total of 36 patients with
diagnosis of ovarian AGCT surgically treated at the Department of Gynecology, Rijeka University Hospital Centre, between
1994 and 2012. Clinical, pathological, and follow-up data were collected. Results. The mean age at diagnosis was 54.5 years with
a range of 24–84. The majority of the patients, 30 (83%), were in FIGO stage IA, 3 (8%) in stage IC1, 1 (3%) in stage IC2, and 2
(6%) in stage IC3. During follow-up period (median 117.5 months, range 26–276), recurrence occurred in 4 patients (12%) with
2 deaths of the disease recorded. In univariate analysis, the 5-year survival rates were signiﬁcantly shorter in patients with FIGO
substage IC (p = 0 019), with positive LVSI (p = 0 022), with presence of necrosis (p = 0 040), and with hemorrhage (p = 0 017).
In univariate analysis, the 5-year disease-free survival rates were signiﬁcantly shorter in patients treated with fertility surgery
(p = 0 004), with diﬀuse growth pattern (p = 0 012), with moderate and severe nuclear atypia (p = 0 032), and with presence of
hemorrhage (p = 0 022). FIGO substage IC proved to be independent predictor for recurrence (OR= 16.87, p = 0 015, and
OR= 23.49, p = 0 023, resp.) and disease-free survival (p = 0 0002; HR 20.84, p = 0 02) at the uni- and multivariate analyses.
Conclusions. FIGO substage IC is predictive of recurrence and disease-free survival in patients with early-stage AGCTs. LVSI,
presence of necrosis and hemorrhage, diﬀuse growth pattern, and nuclear atypia in AGCTs seem to be associated with overall
and disease-free survival, so these pathological features should be taken into consideration when managing patients with AGCT.
1. Introduction
Adult granulosa cell tumors (AGCTs) are an uncommon
type of ovarian neoplasm that represent approximately 2%–
5% of all ovarian malignancies [1, 2]. AGCTs occur more
often in middle-aged and postmenopausal women, with a
peak incidence between 50 and 55 years of age [3]. Clinically,
they are the most common ovarian tumors that secrete
hormones, primarily estrogen, so they can cause endometrial
alterations like hyperplasia and endometrial cancer and
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patients are often presented with irregular vaginal bleeding.
These malignancies are often low grade and have low clinical
stage at presentation, but with an awkward biological poten-
tial for late recurrence [4–6]. The majority of women with
AGCTs are diagnosed at stage I disease, and overall the prog-
nosis for these women is quite good, with several authors
reporting a 10-year survival rate of more than 80% [1, 3].
Nevertheless, the main clinical characteristic of these tumors
is a tendency for late recurrence. Overall, recurrence can be
expected in ~20% of patients with early-stage AGCTs [2, 4, 6].
The average time to recurrence is 5 years after surgical treat-
ment of the primary tumor, but numerous cases of recur-
rence have been reported in the literature even after 20 to
30 years of initial diagnosis [7].
A recent study by Shah et al. demonstrated that a single
somatic point mutation in the transcription factor FOXL2
is present in tumor samples from patients with AGCTs [8].
The studies that followed have proven that FOXL2 mutation
was present in virtually all AGCTs but was negative in other
tumor types [9, 10]. Based on these evidences, this mutation
is now considered as a deﬁning feature of AGCTs and is a
powerful diagnostic tool in the diﬀerential diagnosis of these
tumors [11–14]. Furthermore, there are also indications that
FOXL2 is a driver of AGCT pathogenesis and could be a
potential target for future therapeutics [15].
Surgery is the mainstream of initial treatment aiming at
achieving the histological diagnosis and appropriate staging
[5, 6, 16–20]. Standard surgical treatment of ovarian AGCTs
has changed over the years. Namely, recent published series
suggested a lack of lymph node involvement and recom-
mended abandonment of the lymph node dissection as part
of the primary surgical staging of these tumors [16, 19, 20].
Tumor stage is the most important prognostic factor in
AGCTs [3, 6, 14]. Numerous studies have attempted to
deﬁne other prognostic factors like patient’s age, tumor size,
grade of diﬀerentiation, mitotic activity, and lymphovascular
space invasion [2–5, 16–18, 20–25]. However, their role as
prognostic factors has not been clearly determined, because
of the rarity of these tumors and the need for very long
follow-up period. Determination of reliable and more accu-
rate histopathologic features and biological markers of
ovarian AGCTs is required to aid gynecologic oncologists
for stratiﬁcation of patients into risk groups and to predict
which patient has higher risk for development of recur-
rence to enable the additional reﬁnement of adjuvant treat-
ment recommendations.
Taking into account the abovementioned and existing
contradictory clinical and pathohistological prognostic data,
the aim of our study was to analyze the clinical and pathohis-
tological parameters and their impact on recurrence, overall,
and disease-free survival in a homogeneous group of patients
with adult granulosa cell tumors in clinical stage I disease.
2. Material and Methods
The tumor specimens analyzed in this retrospective study
were obtained from a total of 36 patients with diagnosis
of AGCTs of the ovary surgically treated at the Department
of Gynecology, Rijeka University Hospital Centre, between
1994 and 2012. Pathology databases were used to identify
patients. All available computerized and paper medical
records, including inpatient and outpatient visits at the insti-
tution, were reviewed. Data was collected on patient charac-
teristics, clinical ﬁndings, and all treatment received for
primary or recurrent disease. The study included all consecu-
tive patients for which all clinical data and adequate tumor
specimens were available. We included only the patients
operated on till 2012 to ensure the follow-up of a minimum
of 5 years. All patients were staged according to the new Inter-
national Federation of Gynecology and Obstetrics (FIGO)
classiﬁcation (2014) for ovarian cancer. Only patients with
FIGO stage I disease were included in this retrospective
study. Exclusion criteria included cases with concomitant
diagnosis of another malignancy that was not an adult gran-
ulosa cell tumor or an endometrial carcinoma. Clinical fea-
tures of the patients are presented in Table 1.
All archived histopathology slides for hematoxylin and
eosin (H&E) stain, of the cases that met the inclusion criteria,
were pulled and examined by two expert gynecologic pathol-
ogists (SE and EB). The pathologists who evaluated the slides
in this cohort were completely blinded to the clinical infor-
mation. Clinical and pathological variables included patient
age, surgical procedure, and ﬁnal pathological analysis with
gross appearance of the tumors and detailed microscopic fea-
tures. More speciﬁcally, we analyzed presence of necrosis and
hemorrhage in tumor tissue, the pattern of granulosa cell
growth, and the number of patterns admixed in one tumor.
The predominant growth pattern was evaluated for each
tumor and for the purpose of statistical analysis; the tumors
were divided into two groups: those with predominantly dif-
fuse growth pattern versus tumors with other growth pat-
terns. Nuclear atypia was also evaluated, and tumors were
divided into two groups: tumors with no or with mild nuclear
atypia versus tumors with moderate and severe nuclear aty-
pia. The mitotic index was expressed in terms of the number
of unequivocal mitotic ﬁgures per 10 high-power ﬁelds
(HPF). The slides were screened at low magniﬁcation for
ﬁnding the area with the highest density of mitotic ﬁgures,
and then mitotic counts were performed at HPF in three sets
of ten randomly chosen contiguous ﬁelds. The mitotic index
is expressed as the average number of mitotic ﬁgures per 10
HPF. According to other studies in the literature, we set the
cutoﬀ at 4 mitotic ﬁgures per 10 HPF to divide tumors into
low and high category [23–25]. Lymphovascular space inva-
sion (LVSI) was diagnosed only when viable tumor nests
were observed within endothelial-lined spaces with or with-
out intraluminal red cells or lymphocytes. Areas of potential
artifact, clefts, or tumor cell contamination (torn tissue, free
tumor fragments along the edge of the tissue) were all ruled
out. No attempts were made to diﬀerentiate between lym-
phatic and vascular vessels because of the diﬃculty and lack
of reproducibility that is associated with routine light micros-
copy. We scored LVSI in a dichotomized fashion: positive
(present) or negative (absent). The interobserver concor-
dance was excellent; in individual cases of interobserver
variation, a third reviewer evaluated the discordances. This
group of tumors is composed of various combinations of
granulosa cells, theca cells, and ﬁbroblasts. The presence of
2 Analytical Cellular Pathology
at least 30% of ﬁbroma/thecoma component in tumor tissue
was used to put cases in AGCTs with prominent ﬁbrotheco-
matous component.
The study was approved by the Clinical Medical Hospital
Rijeka Ethics Committee and Faculty of Medicine University
of Rijeka Ethics Committee for biomedical research.
2.1. Statistical Analysis. Statistical analysis was performed
using MedCalc for Windows, version 18 (MedCalc Statistical
Software bvba, Ostend, Belgium). The classical descriptive
methods were used as well as the Fisher exact test and
χ2-test for the comparison of proportions. Mann–Whitney
test was used to compare the medians. Correlation was
studied using Kendall tau rank correlation. The method
of logistic regression was used in order to compute the
odds ratio (OR) for predictors of recurrence in a univari-
ate and multivariate manner. The association of analyzed
parameters with patient overall and disease-free survival
was evaluated using the Kaplan-Meier method, and diﬀer-
ences between survival curves were tested for statistical
signiﬁcance using the log-rank test. Parameters with prog-
nostic signiﬁcance were included in multivariate Cox
regression model. In all tests, the level of signiﬁcance
was set at p < 0 05.
3. Results
3.1. Clinicopathological Features. The median age at diagno-
sis was 54.5 (range 24–84) years. Thirty patients (83%) were
in FIGO stage IA and 6 (17%) in stage IC. None of the
patients were in FIGO stage IB, so all our patient had unilat-
eral disease with slight predominance of the right ovary (19
patients, 53%). Besides that, none of the patients in our
cohort presented with tumor rupture and haematoperito-
neum. The majority of patients were treated by total abdom-
inal hysterectomy with bilateral salpingo-oophorectomy
(TAH+BSO) with or without complete staging. Complete
staging included peritoneal washings, peritoneal biopsies,
appendectomy, and omental sampling with or without pelvic
and paraaortic lymph nodal sampling. Lymphadenectomy
was performed in 6 patients (17%), pelvic with paraaortic
lymphadenectomy in 4 patients, and only pelvic lymphade-
nectomy in 2 patients. There were inconsistency in staging
surgery modalities due to wide treatment era and the unpre-
dictable diagnosis of AGCT. Pelvic and/or paraaortic lymph-
adenectomy were optional procedures, according to the
surgeon’s experience and the intraoperative ﬁndings, so sys-
tematic complete pelvic and paraaortic lymphadenectomy
during primary surgery was done in 1 patient with concom-
itant endometrial carcinoma, and the remaining lymphade-
nectomies were done in patients with larger tumors for
whom we had an intraoperative diagnosis at the frozen
section. Paraaortic lymphadenectomy was not technically
feasible in 2 patients so in those cases only pelvic lymphade-
nectomy was performed. The median number of received
lymph nodes was 20 with a range of 10–36, all of which were
histologically negative. Seven patients were treated with uni-
lateral salpingo-oophorectomy with staging. These were
mostly younger patients with a view to maintaining fertility
or in patients who had a previously operated uterus and other
adnexa due to benign pathology. Seventeen patients (51%)
had endometrial alterations, that is, hyperplasia without aty-
pia was present in 13 patients (39%), complex hyperplasia
with atypia was present in 3 patients (9%), and 1 patient
(3%) had well diﬀerentiated endometrioid adenocarcinoma
of the endometrium, staged according to FIGO classiﬁcation
IB. There were only 3 patients without a specimen of endo-
metrium for evaluation. Four patients were lost to follow-
up. Postoperative adjuvant chemotherapy with 4 cycles of
BEP protocol (bleomycin, etoposide, and cisplatin) was
administered in 3 patients who were in stage IC disease,
and 2 of those patients developed recurrence. In 1 patient
out of the remaining 3 with stage IC disease for which adju-
vant chemotherapy was not administered, recurrent disease
Table 1: Clinical features of the patients with early-stage adult
granulosa cell tumors.
Clinical features (N = 36)
Age (years)
Median 54.5
Range 24–84
FIGO substage Cases (%)
IA 30 (83%)
IB 0
IC1 3 (8%)
IC2 1 (3%)
IC3 2 (6%)
Initial surgical procedure Cases (%)
TAH+BSO 16 (44%)
TAH+BSO+ staging op 13 (36%)
USO (fertility surgery) 7 (20%)
Lymphadenectomy Cases (%)
Not performed 30 (83%)
Performed 6 (17%)
Adjuvant therapy Cases (%)
Surgery only 32 (91%)
Surgery + chemotherapy 3 (9%)
Endometrial pathology Cases (%)
None 16 (49%)
Hyperplasia without atypia 13 (39%)
Hyperplasia with atypia 3 (9%)
Carcinoma 1 (3%)
Recurrence Cases (%)
No 28 (88%)
Yes 4 (12%)
Months to recurrence
Median (range) 40 (6–120)
Follow-up (months)
Median (range) 117.5 (26–276)
Died of disease (N (%)) 2 (6%)
Note: TAH+ BSO: total abdominal hysterectomy with bilateral salpingo-
oophorectomy; USO: unilateral salpingo-oophorectomy.
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occurred. The patients were examined every 3 months for the
ﬁrst 2 years, every 6 months for the next 3 years, and yearly
thereafter. During the follow-up period, recurrence occurred
in 4 patients and 2 of them died of the disease. Among the 4
patients with recurrent disease, only 1 had isolated pelvic
recurrence and the other 3 patients suﬀered multiple recur-
rences: 2, 3, and 5, respectively. Clinical, pathological, and
treatment details of patients with recurrent disease are pre-
sented in Table 2.
The median months to occurrence of ﬁrst recurrence
were 40 with a range of 6–120 months. The date of recur-
rence was determined by clinical examination, imaging stud-
ies, and CA 125 levels. In addition to that, recurrent diseases
of all our patients were treated surgically so histological slides
of recurrent tumor were also available to conﬁrm the recur-
rence. Overall survival was measured from the day of diagno-
sis until the last follow-up visit to the outpatient clinic
(censored patients) or death. Eight of the 32 patients for
whom complete follow-up was available had died, and 6 of
them died due to a cause other than AGCT, so they were also
censored. The median follow-up time was 117.5 months
(range 26–276 months). Disease-free survival was deﬁned
as the time interval from the date of diagnosis to the date of
documented ﬁrst recurrence of disease. If there was no recur-
rence, disease-free survival was determined as the date of last
follow-up.
3.2. Association of Clinicopathological Features with Disease
Recurrence. On gross examination, the median tumor size
was 6.6 cm with a range of 0.7–30 cm. Eight patients (23%)
had tumor size 10 cm or greater. 21 patients (58%) presented
with an entirely solid tumor mass, yellow to gray on the cut
surface; 6 patients (17%) had an exclusively cystic tumor;
and 9 (25%) presented with a combination, cystic, and solid
tumor mass. Necrosis was present in the tumor tissue of 8
(22%) patients and abundant hemorrhage in 10 tumors
(28%). No diﬀerences in the tumor size (p = 0 083), gross
appearance (p = 0 886), and presence of necrosis (p = 1 00)
between patients with and without recurrent disease were
observed. The observed higher frequency of hemorrhage in
the tumor tissue of the patients with recurrent disease did
not reach statistical signiﬁcance (p = 0 056). Besides that, a
weak but statistically signiﬁcant positive correlation between
hemorrhage in the tumor tissue and LVSI was observed
(r = 0 212, p = 0 05).
The majority of tumors, 30 (83%), had at least two (28%)
or three and more (55%) multiple, admixed growth patterns
of granulosa cells. The predominant growth pattern in our
cohort was distributed as follows: 17 (47%) samples with dif-
fuse growth pattern, 8 (22%) microfollicular, 5 (14%) insular,
4 (11%) corded or trabecular, and 2 (6%) macrofollicular.
When we compared the growth pattern with the recurrence
of the disease, a signiﬁcantly higher frequency of diﬀuse
growth pattern was observed in patients who developed
recurrent disease; in fact, in our cohort all patients with
recurrence had predominantly diﬀuse growth pattern in
primary tumor (p = 0 004). Surprisingly, there was no corre-
lation between the tumor size and predominantly diﬀuse
growth pattern; moreover, tumors larger than 10 cm did
not have a higher frequency of multiple growth patterns
(p = 0 913) or higher frequency of predominantly diﬀuse
growth (p = 0 706). There was no diﬀerences in the number
of growth patterns (p = 0 118), grade of cytological atypia
(p = 0 113), mitotic index (p = 1 00), and presence of promi-
nent ﬁbrothecomatous component (p = 0 609) between
patients with and without recurrent disease. We detected
positive LVSI in 11 tumor specimens (31%) but the observed
higher frequency of LVSI in tumor specimens of patients
with recurrent disease did not reach statistical signiﬁcance
(p = 0 075). The diﬀerences of clinicopathological features
between patients with and without recurrent disease are sum-
marized in Table 3.
Univariate analysis revealed a statistical signiﬁcant asso-
ciation with disease recurrence of FIGO substage IC (OR
29.0; CI 2.25–373.79; p = 0 009) and fertility surgery (OR
21.0; CI 1.73–254.29; p = 0 017). Patient age, tumor size,
necrosis, hemorrhage, diﬀuse growth pattern, grade of cyto-
logical atypia, mitotic index, and LVSI were not statistically
signiﬁcant predictors of disease recurrence. On multivariate
analysis, only the FIGO substage retained signiﬁcance
(OR19.34; CI 1.10–339.18; p = 0 043; AUC 0.941) and was
an important prognostic factor for disease recurrence.
3.3. Survival Analysis. The association of analyzed parame-
ters with overall patient survival during follow-up is shown
in Table 4. In the univariate analysis, the 5-year survival rates
were signiﬁcantly shorter in patients with FIGO substage IC
(p = 0 019), with positive LVSI (p = 0 022), with presence of
necrosis (p = 0 040), and with hemorrhage (p = 0 017) in
the tumor tissue. On the multivariate model, the level of sig-
niﬁcance was not retained for neither of the parameters.
The association of analyzed parameters with disease-free
survival of patients is shown in Table 5. In the univariate
analysis, the 5-year disease-free survival rates were signif-
icantly shorter in patientswith FIGOsubstage IC (p = 0 0002),
treated with unilateral salpingo-oophorectomy with staging
(p = 0 004), with predominant diﬀuse growth pattern of
granulosa cells (p = 0 012), with moderate or severe nuclear
atypia of tumor cells (p = 0 032), and with presence of hem-
orrhage in the tumor tissue (p = 0 022). Observed shorter 5-
year disease-free survival rates in patients with positive LVSI
in the tumor tissue only show a strong trend (p = 0 058) so
we suspect that it would also become statistically signiﬁcant
in a larger patient cohort. On the multivariate analysis, only
the FIGO substage retained signiﬁcance (HR 20.84; CI
1.48–292.95; p = 0 02) and was an important independent
prognostic factor for disease-free survival of patients.
4. Discussion
Practically, 80–90% of patients with AGCTs are presented in
FIGO stage I disease [1]. The overall prognosis for these
patients is very good [1, 3, 6]. Surgery is the standard initial
treatment modality for all patients with AGCTs, and postop-
erative adjuvant chemotherapy of AGCT has changed and
evolved over the past decades [19, 26–28]. Despite advances
in therapy and seemingly favorable clinical behavior, some
patients diagnosed with early-stage AGCT suﬀer from
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recurrence and disease-related mortality [16, 25, 29, 30]. As
with other rare tumors, detailed information on the natural
history and optimal management of patients with AGCTs is
limited. In addition to that, its slow progression and required
long-time period of follow-up make it even more diﬃcult to
understand the biological behavior of the disease. So, the
optimal management of patients has not yet been satisfacto-
rily established, and more speciﬁc determination of the high-
Table 3: Clinicopathological characteristics in comparison to recurrence of early-stage adult granulosa cell tumors.
Features All (N = 36) Recurrent disease p value
No (N = 28) Yes (N = 4)
Age (years)
≤55 y 20 (56%) 18 (56%) 2 (50%) 1.00±
>55 y 16 (44%) 14 (44%) 2 (50%)
FIGO substage
IA 30 (83%) 29 (91%) 1 (25%) 0.01±
IC 6 (17%) 3 (9%) 3 (75%)
Surgery
Radical surgery 29 (81%) 28 (88%) 1 (25%) 0.018±
Fertility surgery 7 (19%) 4 (12%) 3 (75%)
Tumor size
<10 cm 26 (77%) 23 (77%) 3 (75%) 1.00±
≥10 cm 8 (23%) 7 (23%) 1 (25%)
Tumor gross appearance
Solid 21 (58%) 19 (59%) 2 (50%) 0.886¶
Cystic 6 (17%) 5 (16) 1 (25%)
Cystic-solid 9 (25%) 8 (25%) 1 (25%)
Growth patterns of AGCT
Only 1 6 (17%) 4 (13%) 2 (50%) 0.118¶
Mixed with 2 patterns 10 (28%) 10 (31%) 0
Mixed with 3 and more 20 (55%) 18 (56%) 2 (50%)
Dominant growth pattern AGCT
Diﬀuse 17 (47%) 13 (41%) 4 (100%) 0.004±
Others 19 (53%) 19 (59%) 0
Grade of cytologic atypia
1 16 (44%) 16 (50%) 0 0.113±
2 and 3 20 (56%) 16 (50%) 4 (100%)
Mitotic index
<4 19 (53%) 17 (53%) 2 (50%) 1.00±
≥4 17 (47%) 15 (47%) 2 (50%)
LVSI
Negative 25 (69%) 24 (75%) 1 (25%) 0.075±
Positive 11 (31%) 8 (25%) 3 (75%)
Necrosis
Absent 28 (78%) 25 (78%) 3 (75%) 1.00±
Present 8 (22%) 7 (22%) 1 (25%)
Hemorrhage
Absent 26 (72%) 25 (78%) 1 (25%) 0.056±
Present 10 (28%) 7 (22%) 3 (75%)
Prominent ﬁbrothecomatous component
Absent 23 (64%) 21 (66%) 2 (50%) 0.609±
Present 13 (36%) 11 (34%) 2 (50%)
±Fisher exact test; ¶chi-squared test; AGCT: adult granulosa cell tumor; LVSI: lymphovascular space invasion.
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risk pathohistological features of AGCTs are required to aid
gynecologic oncologist in the stratiﬁcation of patients into
risk groups and planning of adjuvant therapy.
In this study, we wanted to analyze the clinical and
detailed pathohistological prognostic parameters in a homo-
geneous model of early-staged AGCT patients with long-
term follow-up.
Among our patients, 17 presented with endometrial
alterations, concomitant endometrial carcinoma, or hyper-
plasia, which underlies the need for biopsy of the endome-
trium during conservative procedures in order to exclude a
concomitant neoplasia. This observation is consistent with
other studies conducted [31].
AGCT can aﬀect younger patients and fertility preserva-
tion is an important issue. However, the role of fertility sur-
gery remains unclear. Some studies have found that fertility
surgery was associated with high recurrence and lower sur-
vival rates [2, 32], while others found no diﬀerence in recur-
rence rates between fertility and radical surgery in patients
with stage I disease [33]. In our study, patients who under-
went fertility surgery had more frequently recurrent disease,
and in univariate analysis fertility surgery was associated with
Table 4: Univariate analysis of overall survival in patients with
early-stage adult granulosa cell tumors.
Features N
Died of the
disease
% 5-year
survival
Log-rank test
(χ2-test)
p value
Age (years)
≤55 y 18 1 100% 0.169
>55 y 14 1 88%
FIGO substage
IA 26 1 100% 0.019
IC 6 1 75%
Surgery
Radical
surgery
25 1 95% 0.681
Fertility
surgery
7 1 100%
Tumor size
<10 cm 23 1 100% 0.083
≥10 cm 7 1 83%
Dominant growth pattern AGCT
Diﬀuse 14 2 90% 0.183
Others 18 0 100%
Grade of cytologic atypia
1 15 0 100% 0.256
2 and 3 17 2 93%
Mitotic index
<4 17 1 100% 0.662
≥4 15 1 92%
LVSI
Negative 22 0 100% 0.022
Positive 10 2 83%
Necrosis
Absent 26 1 100% 0.040
Present 6 1 80%
Hemorrhage
Absent 23 0 100% 0.017
Present 9 2 83%
Prominent ﬁbrothecomatous component
Absent 22 1 100% 0.530
Present 10 1 88%
Table 5: Univariate analysis of disease-free survival in patients with
early-stage adult granulosa cell tumors.
Features N
Number of
documented
recurrence
% 5-year
DFS
Log-rank test
(χ2-test)
p value
Age (years)
≤55 y 18 2 94% 0.624
>55 y 14 2 83.5%
FIGO substage
IA 26 1 100% 0.0002
IC 6 3 42%
Surgery
Radical
surgery
25 1 95% 0.004
Fertility
surgery
7 3 71%
Tumor size
<10 cm 23 3 90.5% 0.860
≥10 cm 7 1 83.5%
Dominant growth pattern AGCT
Diﬀuse 14 4 76% 0.012
Others 18 0 100%
Grade of cytologic atypia
1 15 0 100% 0.032
2 and 3 17 4 79.5%
Mitotic index
<4 17 2 94% 0.736
≥4 15 2 83.5%
LVSI
Negative 22 1 95% 0.058
Positive 10 3 78%
Necrosis
Absent 26 3 92% 0.609
Present 6 1 80%
Hemorrhage
Absent 23 1 95% 0.022
Present 9 3 76%
Prominent ﬁbrothecomatous component
Absent 22 2 96% 0.396
Present 10 2 77%
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disease recurrence and shorter disease-free survival but it did
not retain signiﬁcance in a multivariate manner. Neverthe-
less, close monitoring of these patients can be recommended
with hysterectomy and salpingo-oophorectomy after com-
pletion of family planning.
Given the negative lymph nodes in our patients with
lymphadenectomy and low rate of involvement of lymph
nodes at recurrence (only 1 patient in our cohort with pos-
itive retroperitoneal lymph nodes, but only in the third
recorded recurrence), we are in agreement with previously
conducted studies which implicated that staging of AGCTs
should not be extended to lymphadenectomy [16, 18–20,
29, 34]. Opposite to that, Bryk et al. in their study of 164
molecularly deﬁned AGCTs have suggested that patients
in FIGO substage IC might beneﬁt from complete staging
including lymphadenectomy and adjuvant chemotherapy,
although these results were evident only in univariate
analysis [35].
The role of adjuvant chemotherapy for FIGO substage
IC patients is hugely debatable, and for that reason only 3
out of 6 our patients received postoperative adjuvant che-
motherapy with 4 cycles of BEP protocol. Two of our
patients that received adjuvant therapy developed recur-
rence, but it was impossible to draw any meaningful conclu-
sions regarding the role of adjuvant chemotherapy on such a
small sample. Current National Comprehensive Cancer Net-
work (NCCN) guidelines recommend adjuvant chemother-
apy for advanced-stage patients and stage I disease with
high risk factors, but clear deﬁnition of what constitutes a
high risk factor remains controversial. Two recent studies
by Mangili et al. [36] and Wang et al. [37] that analyzed
AGCT patients in FIGO substage IC failed to demonstrate
the beneﬁt of adjuvant chemotherapy. The results of their
studies have shown that adjuvant chemotherapy was not
associated with improved DFS and did not protect patients
against recurrence of the disease. The largest retrospective
study thus far that included a total of 739 patients with 570
stage I and 139 substage IC patients also failed to detect an
association between adjuvant chemotherapy and improved
DFS in any of the subgroups or in the entire study cohort
[38]. The potential serious toxicity of administered BEP che-
motherapy such as myelosuppression and pulmonary disor-
ders with a lack of obvious beneﬁt suggests that new studies
are needed to address the question of decision to administer
chemotherapy in early-stage AGCT [39]. FOXL2 mutation
was associated with increased CYP17 expression, and inhibi-
tion of this enzyme may be achieved by novel agents such as
abiraterone and ketoconazole [40]. This new potential target
for future therapeutics may prove to be more useful and less
toxic and maybe could be considered in the adjuvant setting.
Studies have proposed several risk factors for recurrence
after surgery for AGCT including advanced age, large tumor
size, tumor rupture, LVSI, degree of cytological atypia, and
high mitotic index [1, 3, 18, 20, 33, 41–46]. The eﬀect of the
abovementioned predictors is controversial with diﬀerent
results of studies in the literature. However, we need to know
that conducted studies have important limitations mainly
due to heterogeneity of the population, small number of
patients included, and some of them with not long enough
follow-up period. We have to admit that our study, as well,
has several limitations, including its retrospective nature
and small sample size with small number of incidences
(recurrences and deaths). But the rarity of AGCT makes it
hard to carry out well-designed studies. Advantages of our
study are focusing and analyzing a homogeneous group of
patients with stage I disease minimizing the inﬂuence and
biases of other potential factors like residual disease, higher
stage, and diﬀerent modalities of adjuvant treatment. An
additional strength of our study is long-term follow-up
period with a median of 9.8 years, which is signiﬁcantly lon-
ger compared to some other studies [4, 5, 23, 24, 44].
Age has not been consistently correlated with survival or
recurrence of women with AGCTs [2, 5, 18, 23, 25, 31, 46].
Zhang et al. [43] found that women younger than 50 years
had a 10% survival advantage in a cohort of 376 women.
Additionally, Ayhan et al. [23] reported that women younger
than 60 years survived longer and had less mortality. Con-
trary to these ﬁndings, Bryk et al. [35] have shown that pre-
menopausal patients have higher rate of relapses and in
their study age less than 40 years was associated with
increased rate of relapses. Our study is in accordance with
other conducted studies, and we did not demonstrate diﬀer-
ence in age between groups of patients regarding recurrence,
and age was not a signiﬁcant predictor of overall or disease-
free survival [2, 5, 18, 25].
Thrall et al. [18] in their study demonstrated that tumor
size was the most important predictor of death from dis-
ease, with no disease recurrences noted among women with
primary tumors smaller than 7 cm. Tumor size has been
noted to be an important prognostic factor in many reports
[1–3, 5, 20, 25, 46]. In these series, tumors larger than 10 to
15 cm were associated with an increased risk of recurrence
and death from disease. Conversely, other authors have
suggested that tumor size is not an important prognostic
factor after adjusting for other clinical factors such as stage,
and some studies were unable to validate the prognostic sig-
niﬁcance of tumor size which is consistent with our results
[4, 22, 23, 29, 44].
Disease stage has been demonstrated to be the most
important predictor of survival to date [2, 3, 14–16, 23–25,
33, 43–47]. The results of our study demonstrated that FIGO
substage IC (surgical spill, capsule rupture before surgery,
tumor cells on ovarian surface, and positive peritoneal wash-
ings) is an important and independent prognostic factor for
disease recurrence and recurrence-free survival in patients
with early-stage AGCTs. So, as far as stage is concerned,
our study is in accordance with others and conﬁrms that even
in early-stage patients, higher substage is one of the most
important predictors for recurrence. Only one patient in
our group with recurrent disease had FIGO stage IA disease,
and the remaining three patients were in the IC substage. Our
patient with FIGO stage IA disease had AGCT with predom-
inantly diﬀuse pattern of growth and positive LVSI in the
tumor tissue. She developed ﬁrst recurrence 10 years after
the diagnosis, then second after 14 years, and third after 15
years and unfortunately died of the disease 20 years after
the diagnosis, so we believe that long-term follow-up is nec-
essary in order to obtain reliable data regarding important
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pathohistological features of AGCTs. Most of the studies
that evaluated classical pathohistological features of AGCTs
are older, and today we are aware that these studies of
granulosa cell tumors are suspects because they almost cer-
tainly included tumors that are not granulosa cell tumors;
thus, drawing conclusions regarding the impact on survival
and recurrence are not recommended. However, recent
studies have shown that FOXL2 mutation is a deﬁning
feature of AGCTs so this is important for future studies,
especially those including advanced stage of the disease,
which should include only molecularly deﬁned granulosa
cell tumors [8–15, 35].
We observed more frequent diﬀuse pattern of growth in
AGCTs of patients with recurrent disease. Namely, all our
patients with recurrence had predominantly diﬀuse growth
pattern of neoplastic granulosa cells. Furthermore, diﬀuse
growth pattern was associated with shorter disease-free sur-
vival. Our observations are not in accordance with a study
by Fujimoto et al. [24]. In their study of 27 patients with
AGCT, they have demonstrated that microscopic patterns
of growth were not associated with disease-free survival.
LVSI can be not only a clinical prognostic parameter but
also a sign of invasive and metastatic potential of granulosa
cells. But, in literature there is an extremely wide range of
reported incidence of LVSI in patients with AGCT. For
example, Fox et al. [5] reported lymphatic invasion in only
4 out of 92 cases of granulosa cell tumors (4.3%); on the other
hand, Fujimoto et al. [24] reported LVSI in 11 out of 27 cases
of AGCT (40.7%), which is as a result closer to our incidence
of 31% (11 out of 36 cases). This diﬀerence could be due to
the use of diﬀerent criteria for diagnosis of lymphatic or
blood vessel invasion. We are not sure because some investi-
gators did not describe their criteria. Fujimoto et al. [24] in
their study used criteria of General Rules of the Japanese
Research Society for Gastric Cancer for assessing LVSI, so
they classiﬁed LVSI in 4 categories: none, minimal, moderate,
and considerable. They had patients with AGCT at all stages
of the disease (17 cases stage I, 4 stage II, 5 stage III, and 1
stage IV), so like expected their incidence of LVSI was some-
what higher than ours. Just as well, it was reasonable to rate
LVSI in their patient group where it is expected to have
higher incidence of invasion, but we believe that for our study
group of early-stage AGCT patients, the best way to score
LVSI was in a dichotomized fashion: positive or negative.
Previous data have suggested that mitotic index can be a
prognostic marker in granulosa cell tumors [4, 5, 24, 39],
but this has not been conﬁrmed in all studies and our results
are in accordance with them [1]. Malmstrom et al. [4] dem-
onstrated that patients in stage I disease have signiﬁcantly
shorter survival when having 10 or more mitotic ﬁgures per
10 HPF. In a more recent study by Fujimoto et al. [24], higher
mitotic index and LVSI were independent prognostic factors
of disease-free survival in patients with AGCT. Our results
suggest that positive LVSI is associated with signiﬁcantly
shorter overall survival of patients; moreover, we observed
higher frequency of positive LVSI in tumor specimens of
patients with recurrent disease and shorter 5-year disease-
free survival rates in those patients, but those results are at
the level of strong statistical trend, so we suspect that it would
also become statistically signiﬁcant in a larger patient
cohort. Besides that, an interesting result of our study is a
positive correlation between hemorrhage in the tumor tissue
and LVSI. This observation can be useful for clinical pathol-
ogists when encountering AGCT with abundant hemor-
rhage to examine more carefully lymphovascular spaces
and maybe take a few more samples of tumor tissue for eval-
uation of LVSI.
Some granulosa cell tumors in their microenvironment
have abundant theca cells and ﬁbroblasts. We wanted to
investigate whether such a tumor microenvironment con-
tributes to the aggressiveness of the tumor. The results of
our study did not support this hypothesis, and prominent
ﬁbrothecomatous component in the tumor tissue was not
associated with prognosis in our patients.
5. Conclusions
The key ﬁnding of our study is that FIGO substage IC is an
important and independent prognostic factor for disease
recurrence and recurrence-free survival in patients with
FIGO stage I AGCTs. We believe that additional studies
of LVSI, presence of necrosis and hemorrhage, diﬀuse
growth pattern, and nuclear atypia in early-stage AGCTs
are required because these pathological features seem to be
associated with overall and disease-free survival, so these
should be taken into consideration when managing patients
with AGCT.
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